Bayleaze
2021-10-15
Wow
Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":825229826,"tweetId":"825229826","gmtCreate":1634230305373,"gmtModify":1634230366411,"author":{"id":4092290440523870,"idStr":"4092290440523870","authorId":4092290440523870,"authorIdStr":"4092290440523870","name":"Bayleaze","avatar":"https://static.tigerbbs.com/4cce861b2b176dd8d8c481f6fa88fe0d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/825229826","repostId":1108820000,"repostType":4,"repost":{"id":"1108820000","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634225594,"share":"https://www.laohu8.com/m/news/1108820000?lang=zh_CN&edition=full","pubTime":"2021-10-14 23:33","market":"us","language":"en","title":"Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108820000","media":"Tiger Newspress","summary":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe bi","content":"<p>Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.</p><p><blockquote>Ocugen股价早盘上涨超过10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>印度生物技术公司的股票今天上午向北移动，因为有消息称，新冠肺炎疫苗科瓦克辛获得了印度主题专家委员会对2至18岁儿童的紧急使用批准。这种疫苗是全世界首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen与印度的Bharat Biotech合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于疫苗紧急使用申请的消息。这一关键的监管决定预计随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二至三线COVID-19疫苗参与者。这种策略的问题在于，在这些高价值地区，新型冠状病毒疫苗已经过剩，而且还会有更多疫苗。<b>Novavax</b>例如，备受期待的COVID-19疫苗NVX-CoV2373将于2022年初在美国上市。因此，目前还不完全清楚像Ocugen这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>受此消息影响，Ocugen的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对该疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，该生物技术公司的股价仍应表现良好。如果该疫苗能够在该公司拥有商业许可证的日益拥挤的市场中开辟一个有利可图的利基市场，那么Ocugen最终可能会获得健康且或许相当长期的收入流。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped more than 10% in morning trading<blockquote>Ocugen股价早盘上涨逾10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-14 23:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.</p><p><blockquote>Ocugen股价早盘上涨超过10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>印度生物技术公司的股票今天上午向北移动，因为有消息称，新冠肺炎疫苗科瓦克辛获得了印度主题专家委员会对2至18岁儿童的紧急使用批准。这种疫苗是全世界首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen与印度的Bharat Biotech合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于疫苗紧急使用申请的消息。这一关键的监管决定预计随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二至三线COVID-19疫苗参与者。这种策略的问题在于，在这些高价值地区，新型冠状病毒疫苗已经过剩，而且还会有更多疫苗。<b>Novavax</b>例如，备受期待的COVID-19疫苗NVX-CoV2373将于2022年初在美国上市。因此，目前还不完全清楚像Ocugen这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>受此消息影响，Ocugen的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对该疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，该生物技术公司的股价仍应表现良好。如果该疫苗能够在该公司拥有商业许可证的日益拥挤的市场中开辟一个有利可图的利基市场，那么Ocugen最终可能会获得健康且或许相当长期的收入流。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108820000","content_text":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.\nOcugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.\nOcugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.Novavax's highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.\nIs Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.\nThat said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2109,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/825229826"}
精彩评论